Outcome Comparisons Among the Hangzhou, Chengdu, and UCSF Criteria for Hepatocellular Carcinoma Liver Transplantation after Successful Downstaging Therapies

Journal of Gastrointestinal Surgery

Volumn 17, Issue 6, 2013, Pages 1116-1122

  Lei, Jianyong ^a   Yan, Lunan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Criteria; Downstage; Liver; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER STAGING; CATHETER ABLATION; CHEMOEMBOLIZATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN;

EID: 84877745472     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2140-6     Document Type: Article

References (26)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzrtti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11): 693-9[PMID: 8594428].
2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;6: 1394-1403 [PMID: 11391528].
3. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multi-modal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235: 533-539 [PMID: 11923610].
4. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85: 1726-1732 [PMID: 18580463].
5. Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc. 2011 Dec;43(10): 3813-8 [PMID: 22172852].
6. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002. CA Cancer J. Clin. 2005;55: 74-108 [PMID: 15761078].
7. Lei JY, Yan LN. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful down-staging therapies. J Gastrointest Surg. 2012 Sep 5[Epud ahead of print] [PMID: 22948843].
8. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010 Aug;10(8): 1861-9 [PMID: 20659092].
9. Iwatsuki S, Starzl TE, Sheahan FG, Yokohama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214: 221-228 [PMID: 1656903].
10. Bismuth H, Chiche L, Adan R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation in cirrhotic patients with hepatocellular carcinoma in cirrhosis. Ann Surg 1993;218: 145-151 [PMID: 8393649].
11. th ed. In: LH Sobin, Ch Wittekind (eds). New York, NY: Wiley-Liss, 1997: 74-77.
12. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000;88: 538-543 [PMID: 10649244].
13. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002 Sep;8(9): 765-74 [PMID: 12200775].
14. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007 Sep; 246(3): 502-9 [PMID: 17717454].
15. Fouzas I, Sotiropoulos GC, Lang H, Nadalin S, Beckebaum S, Sgourakis G, et al. Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria. Transplant Proc. 2008 Nov;40(9): 3185-8 [PMID: 19010228].
16. Macaron C, Hanouneh IA, Lopez R, Aucejo F, Zein NN. Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc. 2010 Dec;42(10): 4585-92 [PMID: 21168743].
17. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, et al. The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5: 795-804 [PMID: 15760404].
18. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transpl 2008;8: 2547-2557 [PMID: 19032223].
19. Chapman WC, Doyle MB, Stuart JE, Vachharajani N, Crippin JF, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to down-stage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248: 617-625 [PMID: 18936575].
20. Silva MF, Sherman M. Criteria for liver transplantation for HCC: What should the limits be? Journal of Hepatology. 2011, 55: 1137-1147 [PMID: 21718672].
21. Suh KS, Cho EH, Lee HW, Chin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007;25: 329-333 [PMID: 17960068].
22. Cillo U, Vitale A, Grigoletto F, Gringeri E, D'Amico F, Valmasoni M, et al. intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transpl 2007;7: 972-981 [PMID: 17391137].
23. Kneteman NM, Oberholzer J, Saghier MA, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10: 1201-1311 [PMID: 15376305].
24. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy, implications for transplant eligibility. Ann Surg 2007;245: 435-442 [PMID: 17435551].
25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42: 1208-1236 [PMID: 16250051].
26. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011;55: 814-9 [PMID: 21334400].